Tag: group

The number of digital subscriptions of AS Ekspress Grupp increased by 10% in the Baltic States year-over-year (2^nd quarter: 4%, 1^st six months: 3%) and totalled 244 884 at the end of June.

SINGAPORE, July 11, 2025 (GLOBE NEWSWIRE) -- Premium Catering (Holdings) Limited (“PC” or the “Company”) (Nasdaq: PC), announced that the members approved a share consolidation (“Reverse Stock Split”) of the Company’s authorized and issued Ordinary Shares at a ratio from 1 for 2 to 1 for 18 (the “Range”) at an Extraordinary General Meeting (“EGM”) held today. Following the EGM, the Board of Directors authorized a Reverse Stock Split of 1:9 for all shareholders of record on July 21, 2025. The Company’s Ordinary Shares are expected to begin trading on a Reverse Stock Split adjusted basis on the Nasdaq Capital Market as of the open of trading on July 22, 2025 under the existing ticket symbol of “PC”.

OKOTOKS, Alberta, July 10, 2025 (GLOBE NEWSWIRE) -- (TSX: MTL) Mullen Group Ltd. (“Mullen Group”, “We”, “Our” and/or the “Corporation”) announces that it has closed its previously announced private placement (the “Offering”) of approximately CAD$400.0 million aggregate principal amount senior secured notes due July 10, 2037 (the “Notes”).

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Flutter Entertainment (NYSE: FLUT; LSE: FLTR) (“Flutter”) the world’s leading online sports betting and iGaming operator today announces the extension of its long-term strategic partnership with Boyd Gaming Corporation (“Boyd”) to 2038 and the buyout of Boyd’s 5% stake in FanDuel Group (“FanDuel”), together “the Agreement”.

SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and Drug Administration (“FDA”), to a patient with mild-stage Alzheimer’s disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab, an amyloid targeting therapy. This exploratory work is being conducted in collaboration with Anita Fletcher, M.D., a board-certified neurologist with specialized training in neuroimmunology, who also serves as Director of Neuroscience Clinical Research at AdventHealth Neuroscience Institute in Orlando, Florida.

PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) plans to report Second Quarter 2025 financial results on Tuesday, August 5, 2025. Management will present the results during a conference call and webcast at 5:00 p.m. Eastern.

Kyiv, New York, Dubai, and Philadelphia – July 10, 2025 – VEON Ltd. (Nasdaq: VEON) (“VEON”), a global digital operator, and Cohen Circle Acquisition Corp. I (“Cohen Circle”), a special purpose acquisition company (Nasdaq: CCIR), today announce the execution of non-redemption agreements (“NRAs”) totaling approximately USD 52.3 million with accredited institutional investors, including Helikon and Clearline. These commitments cover approximately 5.05 million CCIR Class A shares, securing the minimum USD 50 million cash condition for the proposed business combination of Kyivstar Group Ltd (“Kyivstar Group”) and Cohen Circle (the “Business Combination”).